Zacks • 3 days ago
Pluristem Therapeutics (PSTI) has completed patient enrollment in a phase II study on PLX-PAD cells for the treatment of intermittent claudication.
Zacks • 4 days ago
TherapeuticsMD, Inc. (TXMD) announced the publication of two manuscripts detailing with the results of the company's pivotal phase III study (Rejoice) in Menopause: The Journal of The North American Menopause Society.
American City Business Journals • 6 days ago
The New England Venture Capital Association announced the addition of five new board members Tuesday, with a focus on investors who have a background in the digital health and biotech industries. "With the additions boasting deep, specific focuses in biotech company creation, pharmaceuticals, and digital health, the appointments support a growing focus on the Life Sciences community, and come at a time when the organization continues to broaden its offerings in that sector," NEVCA said in a press release announcing the moves. New board members have connections to public companies like Johnson & Johnson (JNJ), Alnylam (ALNY) and Epizyme (EPZM), as well as top local venture capital firms like Atlas Venture, Bain Capital Ventures and Flybridge Capital.
Zacks • 6 days ago
AbbVie Inc. (ABBV) announced positive top-line data from a phase III study on its pan-genotypic ribavirin (RBV)-free regimen of glecaprevir/pibrentasvir (G/P) in Japanese patients.
Zacks • 7 days ago
Puma Biotechnology, Inc. (PBYI) has expanded the fourth cohort of the phase II SUMMIT study evaluating its lead candidate PB272 (neratinib) as a single agent in patients with solid tumors who have an activating HER2 mutation (basket study).
Zacks • 7 days ago
Vertex Pharmaceuticals Incorporated (VRTX) announced preliminary financial results for 2016 and issued a financial outlook for 2017 on Jan 8, ahead of a Jan 9 presentation at the JP Morgan healthcare conference in San Francisco.
Zacks • 28 days ago
Epizyme, Inc. (EPZM) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Insider Monkey • last month
There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Carl Icahn and George Soros think. Those hedge fund operators make billions of dollars each […]
Zacks • 2 months ago
Epizyme, Inc.'s (EPZM) lead pipeline candidate, tazemetostat (an EZH2 inhibitor), has received Fast Track designation in the U.S.
Benzinga • 2 months ago
Wedbush analyst David Nierengarten reiterated his Outperform rating on Epizyme Inc (NASDAQ: EPZM ) after the company announced that the FDA has granted fast track designation for tazemetostat in patients ...
EPZM : Summary for Epizyme, Inc. - Yahoo Finance
Epizyme, Inc. (EPZM)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Day's Range||11.15 - 11.70|
|52 Week Range||7.02 - 13.46|
|PE Ratio (TTM)||-6.21|
|Earnings Date||Mar 7, 2017 - Mar 13, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||23.33|